• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Full and Booster Doses of SARS-CoV-2 mRNA-1273 Vaccine Increase Waning Antibody Levels After Completed Vaccination Among Dialysis Patients at a Large Dialysis Organization.

作者信息

Ficociello Linda H, Willetts Joanna, Mullon Claudy, Johnson Curtis, Anger Michael S, Hymes Jeffrey L

机构信息

Global Medical Office, Fresenius Medical Care, Waltham, MS, USA.

Spectra Laboratories, Southaven, MS, USA.

出版信息

Int J Nephrol Renovasc Dis. 2022 Nov 16;15:319-321. doi: 10.2147/IJNRD.S383215. eCollection 2022.

DOI:10.2147/IJNRD.S383215
PMID:36415313
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9675998/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec38/9675998/6810555e976f/IJNRD-15-319-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec38/9675998/6810555e976f/IJNRD-15-319-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec38/9675998/6810555e976f/IJNRD-15-319-g0001.jpg

相似文献

1
Full and Booster Doses of SARS-CoV-2 mRNA-1273 Vaccine Increase Waning Antibody Levels After Completed Vaccination Among Dialysis Patients at a Large Dialysis Organization.在一家大型透析机构中，SARS-CoV-2 mRNA-1273疫苗的全程和加强剂量可提高透析患者完成疫苗接种后逐渐下降的抗体水平。
Int J Nephrol Renovasc Dis. 2022 Nov 16;15:319-321. doi: 10.2147/IJNRD.S383215. eCollection 2022.
2
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.SARS-CoV-2-mRNA 加强疫苗接种逆转免疫功能低下患者的无反应性和早期抗体衰减 - 一项比较实体瘤、多发性骨髓瘤和炎症性肠病患者免疫反应的四期研究。
Front Immunol. 2022 May 12;13:889138. doi: 10.3389/fimmu.2022.889138. eCollection 2022.
3
Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients.透析患者接种SARS-CoV-2 BNT162b2 mRNA疫苗3至6个月后体液免疫反应减弱
J Clin Med. 2021 Dec 23;11(1):64. doi: 10.3390/jcm11010064.
4
Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals.接种 BNT162b2 疫苗加强针 5 个月后老年人对 Delta 和奥密克戎变异株特异性抗体滴度的下降
Front Immunol. 2022 Nov 14;13:1031852. doi: 10.3389/fimmu.2022.1031852. eCollection 2022.
5
Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.mRNA-1273 冠状病毒病 2019 疫苗接种在腹膜透析患者中的抗体反应和安全性 - 维也纳队列。
Front Immunol. 2021 Dec 2;12:780594. doi: 10.3389/fimmu.2021.780594. eCollection 2021.
6
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.COVID-19 疫苗效力下降和加强针的有效性和副作用：来自 ZOE COVID 研究的一项前瞻性社区研究。
Lancet Infect Dis. 2022 Jul;22(7):1002-1010. doi: 10.1016/S1473-3099(22)00146-3. Epub 2022 Apr 8.
7
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.鼻内注射慢病毒加强针可增强正在减弱的、由mRNA疫苗诱导产生的、针对肺黏膜的SARS-CoV-2免疫力。
Mol Ther. 2022 Sep 7;30(9):2984-2997. doi: 10.1016/j.ymthe.2022.04.016. Epub 2022 Apr 27.
8
Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.慢性透析患者 COVID-19 疫苗接种的免疫原性。
Front Immunol. 2021 Jun 30;12:690698. doi: 10.3389/fimmu.2021.690698. eCollection 2021.
9
Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy.影响接受肾脏替代治疗的终末期肾病患者对SARS-CoV-2疫苗体液反应持久性的因素
J Clin Med. 2022 Aug 25;11(17):4984. doi: 10.3390/jcm11174984.
10
Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.COVID-19 加强针接种后免疫反应的持久性及其与 COVID-19 奥密克戎感染的关联。
JAMA Netw Open. 2022 Sep 1;5(9):e2231778. doi: 10.1001/jamanetworkopen.2022.31778.

本文引用的文献

1
Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum.慢性肾脏病范围内对第三剂严重急性呼吸综合征冠状病毒2疫苗的体液反应
Clin J Am Soc Nephrol. 2022 Jun;17(6):872-876. doi: 10.2215/CJN.01770222. Epub 2022 May 12.
2
COVID-19 Vaccine Efficacy and Immunogenicity in End-Stage Renal Disease Patients and Kidney Transplant Recipients.终末期肾病患者和肾移植受者中 COVID-19 疫苗的效力和免疫原性
Curr Transplant Rep. 2022;9(3):174-184. doi: 10.1007/s40472-022-00366-1. Epub 2022 Apr 29.
3
Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response.
Moderna mRNA-1273加强疫苗对体液免疫反应丧失后的全程接种高危慢性透析患者的影响
Vaccines (Basel). 2022 Apr 11;10(4):585. doi: 10.3390/vaccines10040585.
4
Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients.BNT162b2疫苗接种后六个月透析患者体液反应的持久性
Front Med (Lausanne). 2022 Mar 25;9:781888. doi: 10.3389/fmed.2022.781888. eCollection 2022.
5
Antibody maintenance and breakthrough infections 6 months after complete COVID-19 vaccination with the mRNA-1273 and BNT162b2 vaccines in hemodialysis patients.血液透析患者接种mRNA-1273和BNT162b2疫苗完成新冠病毒疫苗全程接种6个月后的抗体维持情况及突破性感染
Clin Kidney J. 2021 Dec 16;15(4):818-819. doi: 10.1093/ckj/sfab282. eCollection 2022 Apr.
6
Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-CoV-2 Vaccine in Dialysis Patients.透析患者对基于mRNA与腺病毒载体的SARS-CoV-2疫苗的体液反应。
Clin J Am Soc Nephrol. 2021 Nov;16(11):1720-1722. doi: 10.2215/CJN.06450521. Epub 2021 Jul 26.